CATalyst Council Reports Cat Clinical Visits Grow 2.7 Percent as U.S. Veterinary Clinical Visits Fall 1.9 Percent

U.S. feline clinical visits at veterinary practices rose 2.7% year over year in Q3 2026, while canine visits fell 3.3%, according to Vetsource data reported by CATalyst Council. Feline visits increased in each of the past 12 quarters, while canine visits declined in 11 of them.

Analysis

The investable signal is a possible shift in veterinary demand mix, not proof of sector growth: feline appointment gains may be offset by weaker canine activity, and visits alone do not establish revenue, treatment intensity, or profit. If the pattern persists, practices could redirect appointment capacity toward cat care, while suppliers with meaningful feline diagnostics or therapeutics exposure may benefit at the margin. IDEXX Laboratories and Zoetis are worth monitoring, but their broad portfolios make species-level sensitivity important to verify; the data do not establish that either is a direct winner. Retailers and service businesses tied to routine canine visits could face pressure, though practice visits are not a reliable proxy for their total sales.

Near term, this is a weak standalone trading catalyst. Over 1–3 months, check whether subsequent practice data confirm the species divergence and whether company disclosures show corresponding changes in product mix, diagnostic volumes, or guidance. Over 6–18 months, persistent divergence could affect practice utilization and supplier mix, but the trend could reverse if owners defer care, practice sampling changes, or canine volumes recover. The contrarian point: twelve quarters of directional consistency sounds structural, but without spend per visit, treatment mix, and dataset coverage it may overstate the earnings signal. No high-conviction position is justified yet.

Key Decisions for Investors

• No immediate sector or single-name trade on this release alone; avoid treating visit counts as a direct revenue forecast.
• Add IDEXX Laboratories and Zoetis to a watchlist; verify feline-versus-canine revenue or diagnostic exposure and subsequent volume commentary before taking a relative-value position.
• Over the next 1–3 months, monitor repeat visit data, spend per visit, and practice utilization. A reversal in the species trend or no corresponding change in company metrics would falsify the mix-shift thesis.
• Reassess only if persistent divergence is corroborated by company disclosures or earnings; absent that confirmation, treat the report as a low-impact industry indicator.